PP
FLNA

PFS Partners’s Filana Therapeutics FLNA Stock Holding History

PFS Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$5.89K – 456
2024
Q3 		$5.89K Hold
200
– – ﹤0.01% 335
2024
Q2 		$2.47K Hold
200
– – ﹤0.01% 381
2024
Q1 		$4.06K Hold
200
– – ﹤0.01% 369
2023
Q4 		$4.5K Hold
200
– – ﹤0.01% 357
2023
Q3 		$3.33K Hold
200
– – ﹤0.01% 374
2023
Q2 		$4.9K Hold
200
– – ﹤0.01% 359
2023
Q1 		$4.82K Hold
200
– – ﹤0.01% 284
2022
Q4 		$5.91K Hold
200
– – 0.01% 253
2022
Q3 		$8.36K Hold
200
– – 0.01% 212
2022
Q2 		$5.62K Hold
200
– – 0.01% 241
2022
Q1 		$7.43K Hold
200
– – 0.01% 235
2021
Q4 		$8.74K Buy
+200
New +$10.5K 0.01% 218

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

PFS Partners's FLNA Position: Q4 2024 in Review

PFS Partners sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 200 shares — an estimated $5.89K sold.

PFS Partners first reported a position in FLNA in Q4 2021 and held it in 12 quarters. The position peaked at $8.74K in Q4 2021. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • PFS Partners reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PFS Partners sold 200 Filana Therapeutics shares in Q4 2024, an estimated $5.89K.
  • PFS Partners first reported a position in Filana Therapeutics in Q4 2021 and held it in 12 quarters.
  • PFS Partners's Filana Therapeutics position peaked at $8.74K in Q4 2021.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on PFS Partners's 13F filing for Q4 2024, filed 27 Jan 2025.